Holly Lofton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Holly Lofton has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Akash Gujral
Department of Surgery, New York University, New York, New York
2 shared publications - Babak J. Orandi
Department of Surgery New York University New York New York USA
2 shared publications Christine Ren-Fielding
2 shared publications- Christine Ren-Fielding
Department of Surgery, New York University Langone Medical Center, New York, USA
2 shared publications - Collin Creange
Department of General Surgery, NYU Langone Medical Center, New York, New York
2 shared publications - Dorry Lidor Segev
Department of Surgery New York University New York New York USA
2 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Wiley in Obesity Science & Practice
- Vol. 12 (6)
Brain and Cardiometabolic Effects of Major Weight Loss in People With Obesity: Preliminary Cohort Findings
Objective: Given the overlap between obesity‐related metabolic and vascular abnormalities and Alzheimer's disease (AD) risk factors, it is critical to determine whether weight loss improves brain and cardiovascular health. This study examined whether ≥ 40% excess‐weight loss is associated with improvements in cardiometabolic risk, brain structure, and cognition. Methods: The study was a longitudinal study of individuals with obesity undergoing metabolic and bariatric surgery or medical/behavioral weight‐loss treatment. Participants were classified at follow‐up as weight‐loss (WL; ≥ 40% excess‐weight loss) or non‐weight‐loss (nWL; < 40%). All completed medical evaluations, structural MRI, and cognitive testing at baseline and 1 year. Results: At 1 year, the WL group exhibited improvements in BMI, HbA1C, inflammatory, metabolic, and lipid profiles. MRI‐based volumetrics revealed increases in subcortical gray‐matter volume and preservation of AD‐vulnerable regions. Cognitive performance remained unchanged. Conclusions: Achieving ≥ 40% excess‐weight loss was associated with improvements in metabolic health and brain structure, including favorable subcortical volume increases. These findings underscore the potential of sustained weight reduction to mitigate risks linked to metabolic syndromes and neurodegeneration. Longer‐term follow‐up is warranted to determine whether continued metabolic improvements lead to detectable cognitive gains and additional brain‐health benefits beyond 1 year.
- 30 October 2026
- Published by Wiley in Obesity Science & Practice
- Vol. 12 (6)
Open AccessBrain and Cardiometabolic Effects of Major Weight Loss in People With Obesity: Preliminary Cohort Findings
Objective: Given the overlap between obesity‐related metabolic and vascular abnormalities and Alzheimer's disease (AD) risk factors, it is critical to determine whether weight loss improves brain and cardiovascular health. This study examined whether ≥ 40% excess‐weight loss is associated with improvements in cardiometabolic risk, brain structure, and cognition. Methods: The study was a longitudinal study of individuals with obesity undergoing metabolic and bariatric surgery or medical/behavioral weight‐loss treatment. Participants were classified at follow‐up as weight‐loss (WL; ≥ 40% excess‐weight loss) or non‐weight‐loss (nWL; < 40%). All completed medical evaluations, structural MRI, and cognitive testing at baseline and 1 year. Results: At 1 year, the WL group exhibited improvements in BMI, HbA1C, inflammatory, metabolic, and lipid profiles. MRI‐based volumetrics revealed increases in subcortical gray‐matter volume and preservation of AD‐vulnerable regions. Cognitive performance remained unchanged. Conclusions: Achieving ≥ 40% excess‐weight loss was associated with improvements in metabolic health and brain structure, including favorable subcortical volume increases. These findings underscore the potential of sustained weight reduction to mitigate risks linked to metabolic syndromes and neurodegeneration. Longer‐term follow‐up is warranted to determine whether continued metabolic improvements lead to detectable cognitive gains and additional brain‐health benefits beyond 1 year.
- 17 June 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (8) , 1100-1110
GLP-1 Receptor Agonist Outcomes, Safety, and Body Mass Index Change in a National Cohort of Patients on Dialysis
Key Points: GLP-1 receptor agonists (GLP-1 RAs) in diabetes and dialysis are associated with 23% lower mortality and 66% higher chance of transplant waitlisting. GLP-1 RAs are not associated with increased risk of acute pancreatitis, biliary complications, or medullary thyroid cancer. GLP-1 RAs are associated with a 32% increased risk of diabetic retinopathy in patients with diabetes on dialysis. Background: Of the 808,000 US patients on dialysis, 60% have diabetes and are eligible for glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Safety and outcomes in this population are unknown. We sought to examine GLP-1 RA real-world safety, efficacy, and weight loss in people with diabetes on dialysis. Methods: In this observational national cohort study (2013–2021), we identified adults with type 2 diabetes on dialysis. The exposure of interest was GLP-1 RA use. Body mass index (BMI) change after dialysis initiation was quantified among patients with two measurements (N=6474). Extended Cox models with inverse probability of treatment weights (censoring for kidney transplant waitlisting) were used to quantify all-cause mortality associated with GLP-1 RAs. Specific safety outcomes (acute pancreatitis, biliary complications, medullary thyroid cancer, and diabetic retinopathy) were assessed. Results: The study included 151,649 patients on incident dialysis with type 2 diabetes. Mean BMI and weight change among GLP-1 RA users were greater than those among nonusers (−1.47 versus −0.61 kg/m2; −4.03 versus −1.47 kg; P < 0.001 for both). The mortality incidence rate was lower among GLP-1 RA users (219.0 versus 279.5 patients/1000 person-years; P < 0.001). GLP-1 RA use was associated with a 23% lower risk of mortality (adjusted hazard ratio [aHR], 0.77; 95% confidence interval [CI], 0.70 to 0.85; P < 0.001); results were consistent among initiates with BMI ≥30 kg/m2. GLP-1 RA use was associated with a 66% higher chance of waitlisting (aHR, 1.66; 95% CI, 1.28 to 2.13; P < 0.001). There was an increased association with diabetic retinopathy (aHR, 1.32; 95% CI, 1.12 to 1.56; P = 0.001), but not with any other safety outcomes. Inferences were consistent across multiple sensitivity analyses. Conclusions: GLP-1 RA use in patients with type 2 diabetes on dialysis was associated with weight loss, reduced mortality risk, and increased likelihood of kidney transplant waitlisting. These real-world data are the strongest evidence to date supporting GLP-1 RA use in this population.
- 17 June 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (8) , 1100-1110
GLP-1 Receptor Agonist Outcomes, Safety, and Body Mass Index Change in a National Cohort of Patients on Dialysis
Key Points: GLP-1 receptor agonists (GLP-1 RAs) in diabetes and dialysis are associated with 23% lower mortality and 66% higher chance of transplant waitlisting. GLP-1 RAs are not associated with increased risk of acute pancreatitis, biliary complications, or medullary thyroid cancer. GLP-1 RAs are associated with a 32% increased risk of diabetic retinopathy in patients with diabetes on dialysis. Background: Of the 808,000 US patients on dialysis, 60% have diabetes and are eligible for glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Safety and outcomes in this population are unknown. We sought to examine GLP-1 RA real-world safety, efficacy, and weight loss in people with diabetes on dialysis. Methods: In this observational national cohort study (2013–2021), we identified adults with type 2 diabetes on dialysis. The exposure of interest was GLP-1 RA use. Body mass index (BMI) change after dialysis initiation was quantified among patients with two measurements (N=6474). Extended Cox models with inverse probability of treatment weights (censoring for kidney transplant waitlisting) were used to quantify all-cause mortality associated with GLP-1 RAs. Specific safety outcomes (acute pancreatitis, biliary complications, medullary thyroid cancer, and diabetic retinopathy) were assessed. Results: The study included 151,649 patients on incident dialysis with type 2 diabetes. Mean BMI and weight change among GLP-1 RA users were greater than those among nonusers (−1.47 versus −0.61 kg/m2; −4.03 versus −1.47 kg; P < 0.001 for both). The mortality incidence rate was lower among GLP-1 RA users (219.0 versus 279.5 patients/1000 person-years; P < 0.001). GLP-1 RA use was associated with a 23% lower risk of mortality (adjusted hazard ratio [aHR], 0.77; 95% confidence interval [CI], 0.70 to 0.85; P < 0.001); results were consistent among initiates with BMI ≥30 kg/m2. GLP-1 RA use was associated with a 66% higher chance of waitlisting (aHR, 1.66; 95% CI, 1.28 to 2.13; P < 0.001). There was an increased association with diabetic retinopathy (aHR, 1.32; 95% CI, 1.12 to 1.56; P = 0.001), but not with any other safety outcomes. Inferences were consistent across multiple sensitivity analyses. Conclusions: GLP-1 RA use in patients with type 2 diabetes on dialysis was associated with weight loss, reduced mortality risk, and increased likelihood of kidney transplant waitlisting. These real-world data are the strongest evidence to date supporting GLP-1 RA use in this population.
- Open Access
- 14 November 2024
- Published by JMIR Publications Inc. in JMIR Diabetes
- Vol. 9 (1) , e58680
Lightening the Load: Generative AI to Mitigate the Burden of the New Era of Obesity Medical Therapy
Highly effective antiobesity and diabetes medications such as glucagon-like peptide 1 (GLP-1) agonists and glucose-dependent insulinotropic polypeptide/GLP-1 (dual) receptor agonists (RAs) have ushered in a new era of treatment of these highly prevalent, morbid conditions that have increased across the globe. However, the rapidly escalating use of GLP-1/dual RA medications is poised to overwhelm an already overburdened health care provider workforce and health care delivery system, stifling its potentially dramatic benefits. Relying on existing systems and resources to address the oncoming rise in GLP-1/dual RA use will be insufficient. Generative artificial intelligence (GenAI) has the potential to offset the clinical and administrative demands associated with the management of patients on these medication types. Early adoption of GenAI to facilitate the management of these GLP-1/dual RAs has the potential to improve health outcomes while decreasing its concomitant workload. Research and development efforts are urgently needed to develop GenAI obesity medication management tools, as well as to ensure their accessibility and use by encouraging their integration into health care delivery systems.
- 14 November 2024
- Published by JMIR Publications Inc. in JMIR Diabetes
- Vol. 9 (1) , e58680
Open AccessLightening the Load: Generative AI to Mitigate the Burden of the New Era of Obesity Medical Therapy
Highly effective antiobesity and diabetes medications such as glucagon-like peptide 1 (GLP-1) agonists and glucose-dependent insulinotropic polypeptide/GLP-1 (dual) receptor agonists (RAs) have ushered in a new era of treatment of these highly prevalent, morbid conditions that have increased across the globe. However, the rapidly escalating use of GLP-1/dual RA medications is poised to overwhelm an already overburdened health care provider workforce and health care delivery system, stifling its potentially dramatic benefits. Relying on existing systems and resources to address the oncoming rise in GLP-1/dual RA use will be insufficient. Generative artificial intelligence (GenAI) has the potential to offset the clinical and administrative demands associated with the management of patients on these medication types. Early adoption of GenAI to facilitate the management of these GLP-1/dual RAs has the potential to improve health outcomes while decreasing its concomitant workload. Research and development efforts are urgently needed to develop GenAI obesity medication management tools, as well as to ensure their accessibility and use by encouraging their integration into health care delivery systems.
- Top Cited PapersOpen Access
- 10 September 2024
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 21 (2) , 135-145
A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass
- 10 September 2024
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 21 (2) , 135-145
Top Cited PapersOpen AccessA randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass
- Open Access
- 9 December 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (3) , 328-337
Antiobesity pharmacotherapy to facilitate living kidney donation
- 9 December 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (3) , 328-337
Open AccessAntiobesity pharmacotherapy to facilitate living kidney donation
- Top Cited PapersOpen Access
Obesity among African American people in the United States: A review
Obesity is a growing public health crisis in the United States and is associated with a substantial disease burden due to an increased risk for multiple complications, including cardiovascular and metabolic diseases. As highlighted in this review, obesity disproportionately affects the African American population, women in particular, regardless of socioeconomic status. Structural racism remains a major contributor to health disparities between African American people and the general population, and it limits access to healthy foods, safe spaces to exercise, adequate health insurance, and medication, all of which impact obesity prevalence and outcomes. Conscious and unconscious interpersonal racism also impacts obesity care and outcomes in African American people and may adversely affect interactions between health care practitioners and patients. To reduce health disparities, structural racism and racial bias must be addressed. Culturally relevant interventions for obesity management have been successfully implemented that have shown benefits in weight management and risk‐factor reduction. Strategies to improve health care practitioner–patient engagement should also be implemented to improve health outcomes in African American people with obesity. When managing obesity in African American people, it is critical to take a holistic approach and to consider an individual's social and cultural context in order to implement a successful treatment strategy. image
Top Cited PapersOpen AccessObesity among African American people in the United States: A review
Obesity is a growing public health crisis in the United States and is associated with a substantial disease burden due to an increased risk for multiple complications, including cardiovascular and metabolic diseases. As highlighted in this review, obesity disproportionately affects the African American population, women in particular, regardless of socioeconomic status. Structural racism remains a major contributor to health disparities between African American people and the general population, and it limits access to healthy foods, safe spaces to exercise, adequate health insurance, and medication, all of which impact obesity prevalence and outcomes. Conscious and unconscious interpersonal racism also impacts obesity care and outcomes in African American people and may adversely affect interactions between health care practitioners and patients. To reduce health disparities, structural racism and racial bias must be addressed. Culturally relevant interventions for obesity management have been successfully implemented that have shown benefits in weight management and risk‐factor reduction. Strategies to improve health care practitioner–patient engagement should also be implemented to improve health outcomes in African American people with obesity. When managing obesity in African American people, it is critical to take a holistic approach and to consider an individual's social and cultural context in order to implement a successful treatment strategy. image
- 1 June 2020
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 91 (6) , AB227
Sa1964 THE DUAL EFFICACY OF PHARMACOTHERAPY WITH INTRAGASTRIC BALLOONS FOR SUSTAINED WEIGHT LOSS - A RETROSPECTIVE ANALYSIS
- 1 June 2020
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 91 (6) , AB227
Sa1964 THE DUAL EFFICACY OF PHARMACOTHERAPY WITH INTRAGASTRIC BALLOONS FOR SUSTAINED WEIGHT LOSS - A RETROSPECTIVE ANALYSIS
- 1 October 2018
- Published by Wolters Kluwer Health in JBJS Reviews
- Vol. 6 (10) , e4
Team Approach: Perioperative Optimization for Total Joint Arthroplasty
* With the shift toward value-based patient care, greater emphasis has been placed on improving patient outcomes, reducing complications, and minimizing hospital costs. Optimal care therefore requires a multidisciplinary approach for perioperative patient optimization and episode management. * Here we review the case of a 48-year-old woman with symptomatic osteoarthritis of the left hip and multiple medical comorbidities. We present appropriate optimization guidelines from a panel of multidisciplinary experts in their respective specialties. * Continued clinical research is critical with regard to perioperative optimization and disease episode management as part of population health initiatives and will enable us to better identify at-risk patients early in the process. This will promote the development of improved evidence-based screening criteria and guidelines allowing for the optimization of patient outcomes, safety, and satisfaction following total joint arthroplasty. * Historically, surgical risk stratification methods have emphasized the appraisal of non-modifiable risk factors. Consequently, this has incentivized surgeons to operate on healthy, low comorbidity burden patients, while avoiding surgical intervention on unhealthy, high-comorbidity patients. Only recently has the medical optimization of high-risk candidates undergoing total joint arthroplasty demonstrated improved outcomes by reducing hospital readmissions when patients undergo total joint arthroplasty after optimization.
- 1 October 2018
- Published by Wolters Kluwer Health in JBJS Reviews
- Vol. 6 (10) , e4
Team Approach: Perioperative Optimization for Total Joint Arthroplasty
* With the shift toward value-based patient care, greater emphasis has been placed on improving patient outcomes, reducing complications, and minimizing hospital costs. Optimal care therefore requires a multidisciplinary approach for perioperative patient optimization and episode management. * Here we review the case of a 48-year-old woman with symptomatic osteoarthritis of the left hip and multiple medical comorbidities. We present appropriate optimization guidelines from a panel of multidisciplinary experts in their respective specialties. * Continued clinical research is critical with regard to perioperative optimization and disease episode management as part of population health initiatives and will enable us to better identify at-risk patients early in the process. This will promote the development of improved evidence-based screening criteria and guidelines allowing for the optimization of patient outcomes, safety, and satisfaction following total joint arthroplasty. * Historically, surgical risk stratification methods have emphasized the appraisal of non-modifiable risk factors. Consequently, this has incentivized surgeons to operate on healthy, low comorbidity burden patients, while avoiding surgical intervention on unhealthy, high-comorbidity patients. Only recently has the medical optimization of high-risk candidates undergoing total joint arthroplasty demonstrated improved outcomes by reducing hospital readmissions when patients undergo total joint arthroplasty after optimization.
- 1 August 2016
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 12 (7) , S157-S158
The Effects Of Commuting On Obesity
- 1 August 2016
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 12 (7) , S157-S158
The Effects Of Commuting On Obesity
- 1 August 2016
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 12 (7) , S157
Use Of Liraglutide For Weight Loss In Patients With Prior Bariatric Surgery
- 1 August 2016
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 12 (7) , S157
Use Of Liraglutide For Weight Loss In Patients With Prior Bariatric Surgery